Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07SDQ
|
|||
| Former ID |
DNC006900
|
|||
| Drug Name |
Curcumin
|
|||
| Synonyms |
curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 3 | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H20O6
|
|||
| Canonical SMILES |
COC1=C(C=CC(=C1)C=CC(=O)CC(=O)C=CC2=CC(=C(C=C2)O)OC)O
|
|||
| InChI |
1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3/b7-3+,8-4+
|
|||
| InChIKey |
VFLDPWHFBUODDF-FCXRPNKRSA-N
|
|||
| CAS Number |
CAS 458-37-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
91276, 521754, 616319, 806710, 855880, 3139269, 7979963, 8136975, 8145866, 8719722, 10319004, 12013839, 12055808, 14803853, 17389087, 24892408, 24892983, 29203996, 44256039, 46493764, 48184781, 48414613, 48414614, 48423182, 48424998, 49854349, 49856278, 50104137, 50104138, 53788771, 56312449, 56313017, 56422380, 57288615, 57408903, 75735540, 81040856, 81054961, 81093229, 85286188, 85789755, 87565556, 87565557, 88806667, 92126156, 92709887, 93165931, 103961572, 104171337, 105852703
|
|||
| ChEBI ID |
CHEBI:3962
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Escherichia coli
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Resulting Metabolite | Tetrahydrocurcumin | |||
| Metabolic Effect | Increase activity | |||
| Description | Curcumin can be metabolized to Tetrahydrocurcumin by Escherichia coli, which results in the increase of the drug's activity. | |||
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
|
Studied Microbe: Bifidobacteriales
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Il10 -/- mice | Experimental Sample | Faeces | |
| Disease or Condition | Colon cancer | |||
| Description | The abundance of Bifidobacteriales was increased by Curcumin. | |||
|
Studied Microbe: Bifidobacteriales
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Wild type 129/SvEv mice | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Bifidobacteriales was decreased by Curcumin. | |||
|
Studied Microbe: Clostridiales
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Il10 -/- mice | Experimental Sample | Faeces | |
| Disease or Condition | Colon cancer | |||
| Description | The abundance of Clostridiales was decreased by Curcumin. | |||
|
Studied Microbe: Coriobacteriales
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Il10 -/- mice | Experimental Sample | Faeces | |
| Disease or Condition | Colon cancer | |||
| Description | The abundance of Coriobacteriales was increased by Curcumin. | |||
|
Studied Microbe: Coriobacteriales
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Wild type 129/SvEv mice | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Coriobacteriales was decreased by Curcumin. | |||
|
Studied Microbe: Lactobacillales
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Il10 -/- mice | Experimental Sample | Faeces | |
| Disease or Condition | Colon cancer | |||
| Description | The abundance of Lactobacillales was increased by Curcumin. | |||
|
Studied Microbe: Lactobacillales
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Wild type 129/SvEv mice | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Lactobacillales was increased by Curcumin. | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7000). | |||
| REF 2 | Nanocurcumin: a promising therapeutic advancement over native curcumin. Crit Rev Ther Drug Carrier Syst. 2013;30(4):331-68. | |||
| REF 3 | Drug Metabolism by the Host and Gut Microbiota: A Partnership or Rivalry?. Drug Metab Dispos. 2015 Oct;43(10):1499-504. | |||
| REF 4 | The Role of Curcumin in Modulating Colonic Microbiota During Colitis and Colon Cancer Prevention. Inflamm Bowel Dis. 2015 Nov;21(11):2483-94. | |||
| REF 5 | Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. Eur J Med Chem. 2008 Aug;43(8):1621-31. | |||
| REF 6 | Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem. 2006 Oct 5;49(20):6111-9. | |||
| REF 7 | Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. | |||
| REF 8 | Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. | |||
| REF 9 | High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005. | |||
| REF 10 | Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloprote... Bioorg Med Chem. 2009 Feb 1;17(3):1290-6. | |||
| REF 11 | Thiazolides: a new class of antiviral drugs. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):667-74. | |||
| REF 12 | A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. | |||
| REF 13 | Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammator... Bioorg Med Chem Lett. 2005 Apr 1;15(7):1793-7. | |||
| REF 14 | Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J Nat Prod. 2009 Apr;72(4):725-31. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.